PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor.

[1] The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.

[2] This hormonal preparation article is a stub.

You can help Wikipedia by expanding it.